Search
Piclamilast
go.drugbank.com/drugs/DB01791ExperimentalThe structure for piclamilast was first elucidated in a 1995 European patent application and exhibits the structural functionalities of cilomilast and roflumilast. … Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects.
Synonyms: 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-p-anisamide, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamideSNS01-T
go.drugbank.com/drugs/DB17302InvestigationalSNS01-T is a gene therapy nanoparticle. … It is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine.
Cadmium
go.drugbank.com/drugs/DB14085ExperimentalAn element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.
Foscenvivint
go.drugbank.com/drugs/DB15034InvestigationalPRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis).
25-desacetylrifapentine
go.drugbank.com/drugs/DB15213Investigational25-desacetylrifapentine is under investigation in clinical trial NCT00023387 (TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine).
AN2898
go.drugbank.com/drugs/DB16039InvestigationalAN2898 is under investigation in clinical trial NCT01301508 (Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-moderate Atopic Dermatitis).
PT-2385
go.drugbank.com/drugs/DB16055InvestigationalPT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).
GED-0507-34-Levo
go.drugbank.com/drugs/DB16109InvestigationalGED-0507-34-Levo is under investigation in clinical trial NCT02808390 (Efficacy and Safety Study of Ged-0507-34-levo for Treatment of UC).
MOR-22
go.drugbank.com/drugs/DB17790ExperimentalMOR-22, a Natural human lymphoblastoid interferon-alpha, is currently being investigated to treat papillomavirus warts in the oral cavity of HIV-positive patients.
Palazestrant
go.drugbank.com/drugs/DB18971InvestigationalPalazestrant is under investigation in clinical trial NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).